Jasper Crashes as Compromised Drug Lot Confounds Urticaria Study
After issues with a batch of Jasper Therapeutics’ investigational antibody led to “lower” therapeutic effects in several patients, analysts at BMO Capital Markets said they “believe investors won’t feel comfortable coming back to the story.”
Jasper Crashes as Compromised Drug Lot Confounds Urticaria Study Read More »
